STE vs WAT vs MMSI vs HSIC vs IART

For growth investors, Merit Medical Systems, Inc.

(MMSI) is the stronger pick with 11. 7% revenue growth year-over-year, versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate STERIS plc (STE) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 6x versus STERIS plc at 34. 5x. On forward P/E, Integra LifeSciences Holdings Corporation is actually cheaper at 5. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: STERIS plc wins at 3. 86x versus Waters Corporation's 4. 70x.

Over the past 5 years, Waters Corporation (WAT) delivered a total return of +11.

3%, compared to -81. 7% for Integra LifeSciences Holdings Corporation (IART). Over 10 years, the gap is even starker: STE returned +220. 0% versus IART's -63. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STERIS plc (STE) is the lower-risk stock at 0.

69β versus Integra LifeSciences Holdings Corporation's 2. 34β — meaning IART is approximately 238% more volatile than STE relative to the S&P 500. On balance sheet safety, STERIS plc (STE) carries a lower debt/equity ratio of 33% versus 195% for Integra LifeSciences Holdings Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Merit Medical Systems, Inc.

(MMSI) is pulling ahead at 11. 7% versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). On earnings-per-share growth, the picture is similar: STERIS plc grew EPS 62. 7% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, MMSI leads at 9. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Waters Corporation (WAT) is the more profitable company, earning 20.

3% net margin versus -31. 6% for Integra LifeSciences Holdings Corporation — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus 4. 2% for IART. At the gross margin level — before operating expenses — WAT leads at 57. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, STERIS plc (STE) is the more undervalued stock at a PEG of 3. 86x versus Waters Corporation's 4. 70x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Integra LifeSciences Holdings Corporation (IART) trades at 5. 8x forward P/E versus 24. 4x for Waters Corporation — 18. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MMSI: 52. 4% to $95. 00.

In this comparison, STE (1.

0% yield) pays a dividend. WAT, MMSI, HSIC, IART do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, STERIS plc (STE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

69), 1. 0% yield, +220. 0% 10Y return). Integra LifeSciences Holdings Corporation (IART) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (STE: +220. 0%, IART: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

STE pays a dividend while WAT, MMSI, HSIC, IART do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.